Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
AU685540B2 - T cell receptor variable transcripts as disease related markers - Google Patents
[go: Go Back, main page]

AU685540B2 - T cell receptor variable transcripts as disease related markers - Google Patents

T cell receptor variable transcripts as disease related markers

Info

Publication number
AU685540B2
AU685540B2 AU10046/95A AU1004695A AU685540B2 AU 685540 B2 AU685540 B2 AU 685540B2 AU 10046/95 A AU10046/95 A AU 10046/95A AU 1004695 A AU1004695 A AU 1004695A AU 685540 B2 AU685540 B2 AU 685540B2
Authority
AU
Australia
Prior art keywords
disease
cell receptors
cell receptor
disease related
related markers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn - After Issue
Application number
AU10046/95A
Other versions
AU1004695A (en
Inventor
Claude Bernard
Jorge Oksenberg
Lawrence Steinman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24059000&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU685540(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of AU1004695A publication Critical patent/AU1004695A/en
Application granted granted Critical
Publication of AU685540B2 publication Critical patent/AU685540B2/en
Anticipated expiration legal-status Critical
Withdrawn - After Issue legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Methods are provided for determining relations between autoimmune degenerative diseases and specific variable regions of T-cell receptors as associated with the host HLA or T-cells associated with combatting neoproliferative diseases. By identifying the particular T-cell receptors which cause or are the disease in mammals, various prophylactic and therapeutic techniques may be employed for inhibiting the attack of the T-cell receptors on the native protein or tissue enhancing the defense. In addition, individuals may be diagnosed as to their propensity for a particular autoimmune disease or the occurrence of such a disease.
AU10046/95A 1990-05-01 1995-01-06 T cell receptor variable transcripts as disease related markers Withdrawn - After Issue AU685540B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51724590A 1990-05-01 1990-05-01
US517245 2000-03-02

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU78729/91A Division AU653527B2 (en) 1990-05-01 1991-05-01 T-cell receptor variable transcripts as disease related markers

Publications (2)

Publication Number Publication Date
AU1004695A AU1004695A (en) 1995-03-16
AU685540B2 true AU685540B2 (en) 1998-01-22

Family

ID=24059000

Family Applications (2)

Application Number Title Priority Date Filing Date
AU78729/91A Ceased AU653527B2 (en) 1990-05-01 1991-05-01 T-cell receptor variable transcripts as disease related markers
AU10046/95A Withdrawn - After Issue AU685540B2 (en) 1990-05-01 1995-01-06 T cell receptor variable transcripts as disease related markers

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU78729/91A Ceased AU653527B2 (en) 1990-05-01 1991-05-01 T-cell receptor variable transcripts as disease related markers

Country Status (10)

Country Link
EP (2) EP0725277A3 (en)
JP (1) JPH05506995A (en)
AT (1) ATE140733T1 (en)
AU (2) AU653527B2 (en)
CA (1) CA2081672A1 (en)
DE (1) DE69121099T3 (en)
DK (1) DK0527199T4 (en)
ES (1) ES2090335T3 (en)
GR (1) GR3021421T3 (en)
WO (1) WO1991017268A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5667967A (en) * 1990-05-01 1997-09-16 The Board Of Trustees Of The Leland Stanford Junior University T-cell receptor varible transcripts as disease related markers
US6464978B1 (en) 1989-03-21 2002-10-15 The Immune Response Corporation Vaccination and methods against multiple sclerosis resulting from pathogenic responses by specific T cell populations
US5614192A (en) * 1989-07-19 1997-03-25 Connective Therapeutics, Inc. T cell receptor peptides as therapeutics for immune-related disease
US5776459A (en) * 1989-07-19 1998-07-07 Connetics Corporation TCR V beta 5 peptides
WO1993022455A1 (en) * 1992-04-30 1993-11-11 Taisho Pharmaceutical Co., Ltd. Method of detecting expression of t-cell antigen receptor gene
US5552300A (en) * 1994-01-13 1996-09-03 T Cell Sciences, Inc. T cell antigen receptor V region proteins and methods of preparation thereof
AU2950195A (en) * 1994-07-01 1996-01-25 Connective Therapeutics Inc. Methods for diagnosing an immune-related disease and choosing an immune-related therapy
DE19629095A1 (en) * 1996-07-18 1998-02-12 Ralf Dr Gold Use of recombinant myelin protein for the treatment of T cell-mediated autoimmune diseases of the peripheral nervous system
NO972556D0 (en) * 1997-06-05 1997-06-05 Forskningsparken I Aas As Method for labeling liquids and objects
WO1999015696A1 (en) * 1997-09-19 1999-04-01 Medelys Laboratories Inc. Method and kit for early diagnosis of autoimmunity and lymphoma in central nervous system
CA2490903A1 (en) * 2002-07-03 2004-01-15 Institute For Scientific Research, Inc. Compositions and methods for the detection of human t cell receptor variable family gene expression

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4874845A (en) * 1984-06-13 1989-10-17 Massachusetts Institute Of Technology T lymphocyte receptor subunit
US4886743A (en) † 1985-04-24 1989-12-12 California Institute Of Technology Diagnostic reagents based on unique sequences within the variable region of the T cell receptor and uses thereof
DE3687014T2 (en) * 1985-05-01 1993-04-01 Asahi Chemical Ind TO DETECT TUMORS CAPABLE OF A CLONED T-CELL AND A T-CELL ANTIGEN RECEPTOR.
US6194561B1 (en) * 1986-03-13 2001-02-27 Roche Molecular Systems, Inc. Characterization and detection of sequences associated with autoimmune diseases
US5340921A (en) * 1986-07-03 1994-08-23 T Cell Sciences, Inc. Γ, δT cell receptor and methods and detection
CA1305912C (en) * 1987-06-22 1992-08-04 Richard J. Albertini Detection of lymphocyte amplification
FI891226A7 (en) * 1988-04-28 1989-10-29 The Board Of Trustees Of The Leland Anti-T-cell receptor determinants for the treatment of autoimmune disease
IL86278A (en) * 1988-05-04 2003-06-24 Yeda Res & Dev Endowing cells with antibody specificity using chimeric t cell receptor
IL95125A (en) † 1989-07-19 1995-07-31 Vandenbark Arthur Allen T-cell receptor peptides a method of selecting and preparing same and pharmaceutical compositions containing them
US5126132A (en) * 1989-08-21 1992-06-30 The United States Of America As Represented By The Department Of Health And Human Services Tumor infiltrating lymphocytes as a treatment modality for human cancer
CA2072356A1 (en) * 1989-12-29 1991-06-30 James L. Urban Diagnosis and treatment of diseases
IL97709A (en) * 1990-03-30 2005-05-17 Brigham & Womens Hospital Use of an mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis

Also Published As

Publication number Publication date
AU1004695A (en) 1995-03-16
DK0527199T3 (en) 1996-10-14
DE69121099T2 (en) 1996-12-12
AU653527B2 (en) 1994-10-06
EP0527199A1 (en) 1993-02-17
CA2081672A1 (en) 1991-11-02
EP0527199B2 (en) 2000-08-30
JPH05506995A (en) 1993-10-14
WO1991017268A1 (en) 1991-11-14
ATE140733T1 (en) 1996-08-15
ES2090335T3 (en) 1996-10-16
EP0725277A2 (en) 1996-08-07
GR3021421T3 (en) 1997-01-31
DE69121099T3 (en) 2001-01-25
EP0527199A4 (en) 1993-03-03
EP0527199B1 (en) 1996-07-24
AU7872991A (en) 1991-11-27
DK0527199T4 (en) 2000-12-04
EP0725277A3 (en) 1996-12-04
DE69121099D1 (en) 1996-08-29

Similar Documents

Publication Publication Date Title
AU685540B2 (en) T cell receptor variable transcripts as disease related markers
Vitale et al. Physical and functional independency of p70 and p58 natural killer (NK) cell receptors for HLA class I: their role in the definition of different groups of alloreactive NK cell clones.
Svensson et al. Aortic dissection and aortic aneurysm surgery: clinical observations, experimental investigations, and statistical analyses part III
PT879282E (en) IMMUNOTHERAPY USING CITOTOXIC T-LYMPHOCYTES (CTL)
WO2002094192A3 (en) Antibodies against tumor necrosis factor delta (april)
TR199802572T2 (en) Scanning methods for detecting compounds suitable for adjusting body weight.
NO970155L (en) Artificial extracellular biological matrix and method of preparation thereof
EP1102988B8 (en) Method of determining the immune response activity of blood and test kit therefor
PT751957E (en) PEPTIDIC FRAGMENTS OF STRESS MICROBIAL PROTEINS AND PHARMACEUTICAL COMPOSITION BASED ON THESE FRAGMENTS FOR THE TREATMENT AND PREVENTION OF INFLAMMATORY DISEASES
Wucherpfennig Insights into autoimmunity gained from structural analysis of MHC–peptide complexes
WO2000026248A3 (en) Tuberculosis diagnostic test
ES2150949T3 (en) REGULATION OF THE ACTIVITY OF LYMPHOCYTES WITH THE AID OF PEPTIDOS HLA.
BR9306345A (en) Methods to suppress the ability of a mammal's t-cells to proliferate and to suppress immune response compositions for use in suppressing the ability of t-cells to proliferate and in suppressing the immune response
UY24270A1 (en) NEW PEPTIDES DERIVED FROM HUMAN PROTEIN 60 BY THERMAL SHOCK FOR THE TREATMENT OF DIABETES, COMPOSITIONS, METHODS AND EQUIPMENT.
ES2051737T3 (en) ANTIGENS, ANTIBODIES AND METHODS FOR THE IDENTIFICATION OF METASTATIC HUMAN TUMORS, AND CELL LINES TO PRODUCE SUCH ANTIBODIES.
WO2004073415A3 (en) Water soluble animal muscle protein product
NO331018B1 (en) In vitro method for the determination of pre-neoplastic and / or neoplastic conditions in mammals by purinergic receptor expression, and the use and kit for such screening.
DK1025849T3 (en) Methods for detecting and treating individuals having abnormal cells expressing HLC-A2 / tyrosinase peptide antigens
Blanco et al. Fossil evidence of frequency range of hearing independent of body size in South American Pleistocene ground sloths (Mammalia, Xenarthra)
ATE221200T1 (en) METHOD FOR DETERMINING SUSPENSION TO DIABETES IN ASYMPTOMATIC PATIENTS
WO2000006597A3 (en) Endogenous constitutively activated g protein-coupled orphan receptors
AU1318797A (en) Peptides and uses thereof for therapy of celiac diseases
WO2000038690A3 (en) Prostaglandin e agonists for treatment of dry eye
AU6953296A (en) Lo-cd2a antibody and uses thereof for inhibiting t cell activation and proliferation
White Texaco's white-collar bigots.